Diabetes management, notably with glucagon-like peptide-1 (GLP-1) agonists and sodium–glucose transport protein 2 (SGLT2) inhibitors, minimizes the MACEs in claudicants [30,31]. Here, GCG is linked to diabetes mellitus.